ライフサイエンスコーパス: biliary obstruction

1 orrectable complications (eg, pseudocysts or biliary obstruction).

2 post-ERC infectious events in patients with biliary obstruction.

3 morbidity because the tumor typically causes biliary obstruction.

4 ing the ERC procedure in tumor patients with biliary obstruction.

5 nt with unresectable disease and features of biliary obstruction.

6 d biliary bypass in the setting of malignant biliary obstruction.

7 is the modality of choice for palliation of biliary obstruction.

8 holedocholithiasis and alternative causes of biliary obstruction.

9 and underused approach to managing bowel and biliary obstruction.

10 2015, including 823 patients with malignant biliary obstruction.

11 isk patients, including those with malignant biliary obstruction.

12 among the groups of patients with malignant biliary obstruction (1.8%), history of bile duct injury

13 Thirteen (42%) patients had intrahepatic biliary obstruction; 27 (87%) patients had involvement o

14 ers, but were rarely present in extrahepatic biliary obstruction, alcoholic fibrosis, or normal liver

15 s-sectional imaging can provide evidence for biliary obstruction and a malignancy arising from the bi

16 Biliary obstruction and cholestasis can cause hepatocell

17 with the reassortants and were monitored for biliary obstruction and mortality.

18 accounted for benign and malignant causes of biliary obstruction and procedural complications.

19 accurate in picking a mass as the cause for biliary obstruction and was able to differentiate a beni

20 of lymphocyte subtypes on the development of biliary obstruction, and coculture and cell transfer exp

21 cobiliary disease, the presence and level of biliary obstruction, and obstruction due to bile duct ca

22 gallbladder disease, high-grade and partial biliary obstruction, and the postcholecystectomy pain sy

23 may be accompanied by features of transient biliary obstruction, and those of pancreatic SO dysfunct

24 Patients with biliary obstruction are at high risk to develop septic c

25 patients with potentially resectable PHC and biliary obstruction between preoperative endoscopic or p

26 n the setting of liver dysfunction caused by biliary obstruction can be associated with increased mor

27 These adverse effects of biliary obstruction can be inhibited by administration o

28 Relief from biliary obstruction can be provided with temporary plast

29 Twenty-two patients with unresectable biliary obstruction caused by cholangiocarcinoma (n = 11

30 uction, Bismuth- Corlette type IV stricture, biliary obstruction caused by gallbladder cancer and whe

31 infections; 10% had graft ischemia; 15% had biliary obstruction/cholangitis; 3% had a combination of

32 e literature addressed therapy for malignant biliary obstruction, choledocholithiasis, and biliary co

33 n BEC proliferation at 15 and 24 hours after biliary obstruction compared with adenovirus control.

34 Patients with extrahepatic biliary obstruction do not necessarily require immediate

35 ing chronic active hepatitis C, extrahepatic biliary obstruction (EBO), and normal liver, using nonis

36 Six patients had biliary obstruction; five were treated percutaneously be

37 Male Sprague-Dawley rats received reversible biliary obstruction for 7 days, and the rat PMN-specific

38 cond group of papers evaluated patients with biliary obstructions from proximal biliary neoplasms.

39 if a patient has the tetrad of pancreatitis, biliary obstruction, gastric outlet obstruction and rapi

40 er, he was found to have acute pancreatitis, biliary obstruction, gastric outlet obstruction and rapi

41 CSEMS), intended for palliation of malignant biliary obstruction, have been used to treat benign bili

42 Activation of hepatic T-lymphocytes driving biliary obstruction in BA is regulated by mDCs by way of

43 f iNKT cells in liver injury associated with biliary obstruction in mice with ligations of the common

44 rning the outcome of patients with malignant biliary obstruction in relationship to microbial isolate

45 by ERCP may provide improved palliation from biliary obstruction in the future.

46 ne the role of B cells in the development of biliary obstruction in the Rhesus rotavirus (RRV)-induce

47 icient Ig-alpha(-/-) mice are protected from biliary obstruction in the RRV-induced mouse model of BA

48 f Tregs in Ig-alpha(-/-) mice did not induce biliary obstruction, indicating that the expanded Tregs

49 at endoscopic biliary drainage for malignant biliary obstruction is a first-line intervention.

50 tine preoperative decompression of malignant biliary obstruction is associated with a higher frequenc

51 Management of biliary obstruction is obligatory in perihilar cholangio

52 Acute biliary obstruction leads to periductal myofibroblasts a

53 , younger patients suspected of having acute biliary obstruction likely benefit from MR cholangiopanc

54 This review focuses on treatment of biliary obstruction, malignant gastric outlet obstructio

55 s short- and long-term outcomes of malignant biliary obstruction (MBO) treatment by percutaneous tran

56 rol group contained 13 PSC patients, 16 with biliary obstruction of varying etiologies (including ben

57 For patients with cancer and biliary obstruction, preoperative biliary stenting appea

58 sfunction in patients with some evidence for biliary obstruction (previously SOD type II, now called

59 ow-risk patients and patients with malignant biliary obstruction, rectal indomethacin was associated

60 In addition, biliary obstruction resulted in increased expression of

61 Biliary obstruction results in a well-characterized chol

62 fter evaluation for radiological evidence of biliary obstruction, the animals were sacrificed and por

63 In the absence of biliary obstruction, the average cost per correct diagno

64 lantation and who presented with symptoms of biliary obstruction were examined.

65 tological picture indicative of extrahepatic biliary obstruction with negligible inflammation/necrosi

66 o be used for palliation of malignant distal biliary obstruction with superior patency to plastic ste